Fig. 5

Combined NAC with PLZ suppresses reactivation of PSCs and enhances chemotherapy sensitivity of PCCs. a Western blotting of indicated proteins in PSC1 and PSC2 cells after treatment with NAC at the IC50 value (6.3 mM or 3.6 mM). The indicated proteins were analyzed in living adherent cells. Ctrl: control treatment with PBS. Treated PSCs were used in the following experiments. b Western blotting of the indicated proteins in NAC-treated PSC1 cells (indicated in lane 2) after re-treatment of indicated agents. These treatments included exposure to SUIT-SN, NAC, PLZ, or combined treatment. c Cell viability assays of NAC-treated PSC1 and PSC2 cells after treatment with the indicated agent. d Western blotting of the indicated proteins in SUIT-2 cells after the indicated treatment. NAC, 5 mM; PLZ, 20 μm; Negative Control, DMSO. e Cell viability assays of SUIT-2 and PANC-1 cells after treatment with indicated agents. f Migration and invasion assays of SUIT-2 cells treated with indicated agents (also see Supplementary figure S5E for PANC-1 cells). Migrated or invaded cell numbers were normalized by the total cell number of each cell. Original magnification, × 100. Scale bar = 100 μm. *P < 0.05; **P < 0.01; ***P < 0.001; n.s, no significance